The dramatic reduction of human, technological, and economic resources in the healthcare sector raises questions about the importance and impact of biomedical and pharmaceutical innovation in the medical care industry. The increase in healthcare spending, both nationally and internationally, is not solely due to the increase in volume and prices, but also to the rapid innovation and interchange of pharmaceutical and biomedical products.
Innovation in pharmaceutical care is a complex and multidimensional phenomenon that, as evidenced by scientific research, contributes positively to health and quality of life, as well as to the development of the research industry and economic growth through increased GDP and employment. The impact of these parameters needs to be considered through systematic multi-criteria evaluation and inevitably requires reforms in the pharmaceutical market and decision-making processes through regulatory interventions.
In this context, it is necessary to strike a balance between cost control due to limited budgets and increased spending due to the flood of innovation, through appropriate structural changes in medical care services, to the extent that the formulation "the future of medical care is technological and innovative" holds true.
This book attempts to approach the subject from the perspective of international experience and practice, with the clear purpose of establishing an evidence-based pharmaceutical policy within the framework of national health policy, as it is of utmost importance to assume the relevant policy and scientific responsibility for the design, management, and control of biomedical and pharmaceutical technology, which shapes the future of medical care.